Israel Englander Ascendis Pharma A/S Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Millennium Management LLC holds 501,690 shares of ASND stock, worth $65.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

501,690

Previous 473,449 5.96%

Holding current value

$65.6 Million

Previous $64.6 Million 16.04%

% of portfolio

0.04%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $3.19 Million - $4.33 Million	28,241 Added 5.96%	501,690 $74.9 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $13.5 Million - $17.1 Million	111,389 Added 30.77%	473,449 $64.6 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $41.9 Million - $54.1 Million	339,669 Added 1516.99%	362,060 $54.7 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $1.93 Million - $2.85 Million	22,391 New	22,391 $2.82 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $1.89 Million - $2.51 Million	-19,009 Reduced 71.64%	7,524 $919,000
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $3.23 Million - $4.23 Million	-38,390 Reduced 59.13%	26,533 $2.74 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $7.2 Million - $10.8 Million	-92,241 Reduced 58.69%	64,923 $6.04 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $3.23 Million - $4.29 Million	31,568 Added 25.13%	157,164 $18.4 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $7.47 Million - $9.97 Million	-58,788 Reduced 31.88%	125,596 $16.9 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $19.8 Million - $31.1 Million	175,906 Added 2074.85%	184,384 $29.4 Million
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $7.36 Million - $8.79 Million	-60,532 Reduced 87.71%	8,478 $1.12 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $2.12 Million - $2.94 Million	-16,981 Reduced 19.75%	69,010 $8.89 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $5.34 Million - $6.46 Million	-35,347 Reduced 29.13%	85,991 $14.3 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $11.6 Million - $13.3 Million	-86,280 Reduced 41.56%	121,338 $18.7 Million
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $6.92 Million - $9.74 Million	-62,459 Reduced 23.13%	207,618 $30.7 Million
Q1 2020 May 14, 2020	SELL	$97.01 - $145.11 $21.2 Million - $31.7 Million	-218,685 Reduced 44.74%	270,077 $30.4 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $47.7 Million - $72.6 Million	-521,581 Reduced 51.62%	488,762 $68 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $10.2 Million - $12.7 Million	-106,611 Reduced 9.54%	1,010,343 $97.3 Million
Q2 2019 Aug 15, 2019	BUY	$107.11 - $132.09 $117 Million - $144 Million	1,089,778 Added 4010.08%	1,116,954 $129 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $145 Million - $178 Million	-1,351,133 Reduced 98.03%	27,176 $1.04 Million
Q1 2019 May 14, 2019	BUY	$62.15 - $129.99 $74.2 Million - $155 Million	1,194,634 Added 650.41%	1,378,309 $162 Million
Q4 2018 Feb 14, 2019	SELL	$55.16 - $69.67 $1.79 Million - $2.26 Million	-32,379 Reduced 14.99%	183,675 $11.5 Million
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $22.4 Million - $26.8 Million	-351,169 Reduced 61.91%	216,054 $15.3 Million
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $5.77 Million - $7.28 Million	-98,504 Reduced 14.8%	567,223 $37.7 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $5.26 Million - $9.18 Million	134,936 Added 25.42%	665,727 $43.5 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $587,696 - $742,063	18,377 Added 3.59%	530,791 $21.3 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $13.8 Million - $19 Million	512,414	512,414 $18.6 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.3B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account